Your browser doesn't support javascript.
loading
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
Pan, Lijia; Cheng, Cheng; Duan, Peiwen; Chen, Kai; Wu, Yeming; Wu, Zhixiang.
Affiliation
  • Pan L; Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China.
  • Cheng C; Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China.
  • Duan P; Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China.
  • Chen K; Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China.
  • Wu Y; Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China.
  • Wu Z; Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, 200092, China.
J Exp Clin Cancer Res ; 40(1): 255, 2021 Aug 12.
Article in En | MEDLINE | ID: mdl-34384466
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acrylamides / Receptors, Cytoplasmic and Nuclear / Karyopherins / Hydrazines / Neuroblastoma Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acrylamides / Receptors, Cytoplasmic and Nuclear / Karyopherins / Hydrazines / Neuroblastoma Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Type: Article Affiliation country: China